



ASX ANNOUNCEMENT

9 October 2017

Cynata to Increase Exposure in Japan

Appointment of highly regarded investor relations firm and presentation at leading biotech conference, BioJapan

Key highlights:

- Cynata to increase investor exposure in Japan, a key geography, through recent engagement with Finantec Co. Ltd., a highly regarded Japan-based investor relations firm
- Finantec will develop a specialised investor communications program to further raise Cynata's profile in Japan, which is already strong as a result of the Fujifilm strategic partnership
- Additionally, Cynata to present at the BioJapan 2017 conference (11th – 13th of October), a premier industry conference attended by over 15,000 industry, investor and media delegates

Melbourne, Australia; 9 October 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that it has engaged Finantec Co., Ltd, a highly regarded Japan-based investor relations firm with strong connections to high net worth and institutional investors in Japan.

The engagement marks a new phase in Cynata's global exposure to sophisticated investors with an interest in emerging stem cell and regenerative medicine companies. Tokyo-based Finantec will develop and manage specialist investor communication programs in Japan to further raise Cynata's profile among the Japanese investment community.

Its strategic partnership with Japanese leading regenerative medicine company Fujifilm has resulted in an already strong profile in the Japanese media for Cynata. The partnership saw Fujifilm take a \$4m equity stake in the Company and a license option agreement worth up to \$60m, plus royalties.

"We look forward to building our exposure to the Japanese investor audience, especially given their knowledge of and interest in the regenerative medicine sector. The Japanese economy is the third largest in the world and is on its longest growth streak in more than a decade, so the time is right for us to increase our awareness among local Japanese investors", said Dr Ross Macdonald, Cynata Chief Executive Officer.

"Cynata is a very exciting company at an important phase in its growth. The investment opportunity represented by this promising company, especially given the strategic equity stake taken by Fujifilm, makes it a highly attractive company for our investor network in Japan", said Mr Masaki Kai, President of Finantec.

Additionally, Cynata will present at the "Emerging Technologies and Products in Regenerative Medicine" session at the forthcoming BioJapan 2017 conference being held on the 11th – 13th of



October. BioJapan is the premier Japanese pharmaceutical and biotech industry conference attended by over 15,000 industry, investor and media delegates.

Ends

CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, ross.macdonald@cynata.com
Daniel Paproth, Australia Media Contact, 0421 858 982 , daniel.paproth@mcpartners.com.au
Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus' novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata's unique "off-the-shelf" Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.